Lenalidomide (Revlimid) is a derivative of thalidomide. Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers. Lenalidomide has significantly improved overall survival in myeloma (which generally carries a poor prognosis), although toxicity remains an issue for users.
Blood. 2021 Dec 23;138(25):2655-2669.
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody
Lenalidomide purchased from AbMole
BMC Biol. 2021 May 20;19(1):108.
Very long intergenic non-coding (vlinc) RNAs directly regulate multiple genes in cis and trans
Lenalidomide purchased from AbMole
Int Immunopharmacol. 2015 Sep;578-87.
Resveratrol attenuates hypoxia-induced neurotoxicity through inhibiting microglial activation.
Lenalidomide purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | HL60, MOLM13 and NB4 cells |
Preparation method | Spectrophotometric quantification of cell proliferation was assayed by the water soluble tetrazolium salt-1 (WST-1) (Roche Ltd, Basel, Switzerland) based colorimetric assay. This tetrazolium salt is reduced extracellularly to formazan dye by enzymes of the plasma membrane oxidoreductase. (122) The primary reductant is NADH derived from the TCA of the mitochondria. Hence, WST-1 is converted by metabolically active cells and was employed to measure cell proliferation. The cell lines HL60, MOLM13 and NB4 were plated in triplicate (20×103 cells/well) in a 96-well microplate and treated with either LND (1, 5, 20, 50, 100, 200, and 500 µM) . |
Concentrations | 1, 5, 20, 50, 100, 200, and 500 µM |
Incubation time | 48 h |
Animal Experiment | |
---|---|
Animal models | NOD/scid/gamma (NSG) mice |
Formulation | 10% DMSO, 70% PEG300 |
Dosages | 50 mg/kg daily |
Administration | i.p. |
Molecular Weight | 259.26 |
Formula | C13H13N3O3 |
CAS Number | 191732-72-6 |
Solubility (25°C) | DMSO 34 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related TNF-alpha Products |
---|
C25-140
C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity. |
AX-024
AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. |
1,4-Dicaffeoylquinic acid
1,4-Dicaffeoylquinic acid (1,4-DCQA) is a phenylpropanoid from Xanthii fructus, inhibits LPS-stimulated TNF-α production. |
UCB-9260
UCB-9260 is an orally active small molecule that inhibits tumor necrosis factor (TNF) signaling through an asymmetrical form of a stable trimer. UCB-9260 is more selective to tumor necrosis factor than other superfamily members and binds to tumor necrosis factor Kd The value is 13 nM. |
UTL-5g
UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.